Li SG, Li L. Targeted therapy in HER2-positive breast cancer. Biomed Rep. 2013;1:499-505. Abstract
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734. Abstract
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791-800. Abstract
National Comprehensive Cancer Network (NCCN) Guidelines®. Invasive breast cancer. Version 2.2016.
Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-2099. Abstract
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119. Abstract
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734. Abstract
H.R. 3590-686 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ucm216146.pdf. Accessed December 14, 2016.
Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2016. doi: 10.1001/jama.2016.18305. [Epub ahead of print]
Burdaeva ON, Alexeev SM, Sehlepen KG, et al. Efficacy and safety of BCD-022, trastuzumab biosimilar, compared to Herceptin®: results of international multicenter randomized double blind study in patients with HER2+ mBC. In: Program and abstracts of the Congress of the European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. Abstract 3854.
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-1949. Abstract
Caudle AS, Hunt KK, et al. The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr Opin Obstet Gynecol. 2011;23:31-36. Abstract
Van Minckwitz G, Kaufmann M, Kuemmel S, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis [ASCO abstract 1028]. J Clin Oncol. 2011;29(suppl).
Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124:689-699. Abstract
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32. Abstract
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284.
Clinicaltrials.gov. Efficacy and safety study of ABP 980 compared with trastuzumab in subjects with HER2 positive early breast cancer (Lilac). https://clinicaltrials.gov/ct2/show/NCT01901146. Accessed December 14, 2016.
Clinicaltrials.gov. A study of pertuzumab in addition to chemotherapy and trastuzumab as adjuvant therapy in participants with human epidermal growth receptor 2 (HER2)-positive primary breast cancer. https://clinicaltrials.gov/ct2/show/NCT01358877. Accessed December 14, 2016.
Hurvitz SA, Martin M, Symmans WF, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (TDM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE) [ASCO abstract 500]. J Clin Oncol. 2016;34(suppl).
Harbeck N, Gluz O, Christgen M, et al. Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. In: Program and abstracts of the 38th Annual San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, Texas. Abstract S5-03.
Clinicaltrials.gov. T-DM1 vs paclitaxel/trastuzumab for breast (ATEMPT trial). https://clinicaltrials.gov/ct2/show/NCT01853748. Accessed December 14, 2016.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

Sara A. Hurvitz, MD, FACP

Director, Breast Cancer Clinical Research Program, Associate Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

Disclosures

Disclosure: Sara A. Hurvitz, MD, FACP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Cascadian, Genentech, Inc., GlaxoSmithKline, Lilly, Mediavation Inc., Merrimack, PUMA,

Dr Hurvitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Hurvitz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Hope S. Rugo, MD

Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Disclosures

Disclosure: Hope S. Rugo, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Genomic Health
Received grants for clinical research from: Amgen Inc., BioMarin Inc., Eisai Inc., Genentech, Inc., GlaxoSmithKline, Lilly, Macrogenics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI, Pfizer Inc., Plexxikon

Dr Rugo does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Rugo does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Roderick A Smith, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Roderick A Smith, MS, has disclosed no relevant financial relationships.

CME Reviewer(s)

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer

Authors: Sara A. Hurvitz, MD; Hope S Rugo, MD
CME / ABIM MOC Released: 12/21/2016
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/21/2017

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

The goal of this activity is to increase understanding about the role of biologic therapies, and the potential role of novel biosimilars, in the care for patients with human epidermal growth factor receptor 2 (HER2)+ breast cancer across the disease spectrum.

Upon completion of this activity, learners will have:

Increased knowledge regarding the clinical trial evidence of biologics and biosimilars in the management of HER2-positive breast cancer across the continuum of disease
Greater competence related to the selection of evidence-based regimens for patients with HER2- positive breast cancer

Disclosures

Moderator(s)

Sara A. Hurvitz, MD, FACP

Director, Breast Cancer Clinical Research Program, Associate Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

Disclosures

Disclosure: Sara A. Hurvitz, MD, FACP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Cascadian, Genentech, Inc., GlaxoSmithKline, Lilly, Mediavation Inc., Merrimack, PUMA,

Dr Hurvitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Hurvitz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Hope S. Rugo, MD

Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Disclosures

Disclosure: Hope S. Rugo, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Genomic Health
Received grants for clinical research from: Amgen Inc., BioMarin Inc., Eisai Inc., Genentech, Inc., GlaxoSmithKline, Lilly, Macrogenics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI, Pfizer Inc., Plexxikon

Dr Rugo does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Rugo does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Roderick A Smith, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Roderick A Smith, MS, has disclosed no relevant financial relationships.

CME Reviewer(s)

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer

Authors: Sara A. Hurvitz, MD; Hope S Rugo, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 12/21/2016

Valid for credit through: 12/21/2017

processing....

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

Sara A. Hurvitz, MD, FACP

Hope S. Rugo, MD

Editor(s)

Roderick A Smith, MS

CME Reviewer(s)

Amy H. Seung, PharmD, BCOP

Peer Reviewer

CME / ABIM MOC

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer

Target Audience and Goal Statement

Disclosures

Moderator(s)

Sara A. Hurvitz, MD, FACP

Hope S. Rugo, MD

Editor(s)

Roderick A Smith, MS

CME Reviewer(s)

Amy H. Seung, PharmD, BCOP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Considerations in Maximizing Outcomes in HER2-Positive Breast Cancer